

VentriPoint Diagnostics Ltd.

09:06 19 Nov 2018

VentriPoint Diagnostics says its innovative heart machine can also analyse 3D echo images

VentriPoint Diagnostics Ltd (CVE:VPT) says it has extended its reach into the potential heart imaging market.

The Toronto-based medtech group said that its VMS+ software approved for analysis of all four chambers of the heart can be used for the analysis of 3D echo images generated by any commercially available 3D echocardiography system.

READ: VentriPoint Diagnostics receives order for its VMS Plus - from leading cardiac hospital in Toronto

"This extends our product line to a software solution that increases our footprint in the cardiac medical imaging market," added the firm in a brief regulatory statement.

Ventripoint's heart analysis machine provides medics with a more efficient and cost-effective method for evaluating cardiac volumes and ejection fractions.

Its accuracy already matches that of the MRI (Magnetic resonance imaging (MRI) scan), the gold standard, so there is a significant opportunity for this unique piece of equipment in the market.

"We are looking forward to offering cardiac centres the opportunity to purchase the VMS+ Software to complement their existing 3D echo equipment," said Desmond Hirson, president of Ventripoint Diagnostics.

Ventripoint's strategy is to build value for customers by providing tools to improve clinical outcomes and standard of care for pediatric and adult cardiac patients.

Last week, the group unveiled another boost for its technology - an agreement with the Government of Canada to develop further its heart monitoring system.

The National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) will provide advisory support and conditional funding to share costs of a project designed to accelerate the company's VMS+ system's next-generation product.

Shares are at \$0.185 in Toronto at the time of writing.

Contact Giles Gwinnett at giles@proactiveinvestors.com

Follow Giles on Twitter @Gile74

Price: C\$0.15

Market Cap: C\$9.08M

1 Year Share Price Graph



Share Information

Code: VPT

Listing: TSX-V

52 week High Low
C\$0.29 C\$0.10

Sector: Health Care, Equipment & Services

Website: www.ventripoint.com

Company Synopsis:

Ventripoint (TSXV: VPT) has redesigned VMS to meet the demands of every market. Preparing to move beyond the Left and Right Ventricle to become the first platform to offer 3D volumes for all cardiac chambers, with accuracy equivalent to MRI. all from the convenience of 2D Ultrasound.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.